医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
30期
227-228
,共2页
陈海秋%高晓林(通讯作者)
陳海鞦%高曉林(通訊作者)
진해추%고효림(통신작자)
耐甲氧西林金黄色葡萄球菌%临床分布%耐药性
耐甲氧西林金黃色葡萄毬菌%臨床分佈%耐藥性
내갑양서림금황색포도구균%림상분포%내약성
MRSA%Clinical distribution%Drug resistance
目的:调查医院2011年1月-2012年12月分离的耐甲氧西林金黄色葡萄球菌的耐药趋势,为临床治疗提供依据。方法收集送检标本中分离的耐甲氧西林金黄色葡萄球菌,按照全国临床检验规程分离,并采用美国临床实验室标准化研究所(CLSI)推荐的K-B法进行药敏试验。结果共分离出22株耐甲氧西林金黄色葡萄球菌,以痰标本分离率最高,占68.18%,其次分别是分泌物、清洁中段尿分别占:18.18%、13.64%;耐甲氧西林金黄色葡萄球菌对利奈唑烷、万古霉素的耐药率为0,对青霉素、甲氧西林的耐药率达到100%,对林可酰胺类、氨基糖甙类的耐药率也达70%、50%以上。结论对耐甲氧西林金黄色葡萄球菌进行及时鉴定与药敏分析,把握其耐药趋势,可有效指导临床合理用药。
目的:調查醫院2011年1月-2012年12月分離的耐甲氧西林金黃色葡萄毬菌的耐藥趨勢,為臨床治療提供依據。方法收集送檢標本中分離的耐甲氧西林金黃色葡萄毬菌,按照全國臨床檢驗規程分離,併採用美國臨床實驗室標準化研究所(CLSI)推薦的K-B法進行藥敏試驗。結果共分離齣22株耐甲氧西林金黃色葡萄毬菌,以痰標本分離率最高,佔68.18%,其次分彆是分泌物、清潔中段尿分彆佔:18.18%、13.64%;耐甲氧西林金黃色葡萄毬菌對利奈唑烷、萬古黴素的耐藥率為0,對青黴素、甲氧西林的耐藥率達到100%,對林可酰胺類、氨基糖甙類的耐藥率也達70%、50%以上。結論對耐甲氧西林金黃色葡萄毬菌進行及時鑒定與藥敏分析,把握其耐藥趨勢,可有效指導臨床閤理用藥。
목적:조사의원2011년1월-2012년12월분리적내갑양서림금황색포도구균적내약추세,위림상치료제공의거。방법수집송검표본중분리적내갑양서림금황색포도구균,안조전국림상검험규정분리,병채용미국림상실험실표준화연구소(CLSI)추천적K-B법진행약민시험。결과공분리출22주내갑양서림금황색포도구균,이담표본분리솔최고,점68.18%,기차분별시분비물、청길중단뇨분별점:18.18%、13.64%;내갑양서림금황색포도구균대리내서완、만고매소적내약솔위0,대청매소、갑양서림적내약솔체도100%,대림가선알류、안기당대류적내약솔야체70%、50%이상。결론대내갑양서림금황색포도구균진행급시감정여약민분석,파악기내약추세,가유효지도림상합리용약。
OBJECTIVE To investigate the tendency of drug resistance of MRSA isolated from Jan 2006 to Dec 2010, so as to provide reliable evidence for clinical treatment. METHODS The MRSA strains isolated from the submitted specimens were col ected, the pathogens were isolated and identified according to the national clinical test procedures. The antimicrobial susceptibility testing was performed by using K-B method. RESULTS Altogether 22 MRSA strains have been isolated, 68.18% of which were derived from sputum, and the rest of the pathogens were successively derived from the secretion 18.18% and the urine 13.64%; the drug resistance rates of MRSA against linezolid and vancomycin 0%, the resistance rate to penicil in and methicil in was 100%, the resistance rate to lincosamides and aminoglycosides were higher than 50% and 70%. CONCLUSION It is effective to direct the reasonable clinical medication through identifying MRSA strains and performing the drug susceptibility testing in a timely manner as wel as grasping the tendency of drug resistance.